SEARCH

SEARCH BY CITATION

References

  • 1
    Vajdic CM, McDonald SP, McCredie MR et al. Cancer incidence before and after kidney transplantation. JAMA 2006; 296: 28232831.
  • 2
    Webster AC, Craig JC, Simpson JM, Jones MP, Chapman JR. Identifying high risk groups and quantifying absolute risk of cancer after kidney transplantation: A cohort study of 15,183 recipients. Am J Transplant 2007; 7: 21402151.
  • 3
    Kauffman HM, Cherikh WS, McBride MA, Cheng Y, Hanto DW. Post-transplant de novo malignancies in renal transplant recipients: The past and present. Transplant Int 2006; 19: 607620.
  • 4
    Maisonneuve P, Agodoa L, Gellert R et al. Cancer in patients on dialysis for end-stage renal disease: An international collaborative study. Lancet 1999; 354: 9399.
  • 5
    EBPG Expert Group on Renal Transplantation. European best practice guidelines for renal transplantation. Section IV: Long-term management of the transplant recipient. IV.6.1-3, Cancer risk after renal transplantation. Nephrol Dial Transplant 2002; 17 (4 Suppl): 3136.
  • 6
    Kasiske BL, Vazquez MA, Harmon WE et al. Recommendations for the outpatient surveillance of renal transplant recipients. American Society of Transplantation. J Am Soc Nephrol 2000; 15 (11 Suppl): S186.
  • 7
    Martinez JC, Otley CC, Stasko T et al. Defining the clinical course of metastatic skin cancer in organ transplant recipients: A multicenter collaborative study. Arch Dermatol 2003; 139: 301306.
  • 8
    Saraiya M, Glanz K, Briss PA et al. Interventions to prevent skin cancer by reducing exposure to ultraviolet radiation: A systematic review. Am J Prev Med 2004; 27: 422466.
  • 9
    Cowen EW, Billingsley EM. Awareness of skin cancer by kidney transplant patients. J Am Acad Dermatol 1999; 40(5Pt 1): t-701.
  • 10
    Clowers-Webb HE, Christenson LJ, Phillips PK et al. Educational outcomes regarding skin cancer in organ transplant recipients: Randomized intervention of intensive vs standard education. Arch Dermatol 2006; 142: 712718.
  • 11
    Denits-Pensy M, Forrest GN, Cross AS, Hise MK. The use of vaccines in adult patients with renal disease. Am J Kidney Dis 2005; 46: 9971011.
  • 12
    Cavdar C, Sayan M, Sifil A et al. The comparison of antibody response to influenza vaccination in continuous ambulatory peritoneal dialysis, hemodialysis and renal transplantation patients. Scand J Urol Nephrol 2003; 37: 7176.
  • 13
    Koutsky LA, Holmes KK, Critchlow CW et al. A cohort study of the risk of cervical intraepithelial neoplasia grade 2 or 3 in relation to papillomavirus infection. N Engl J Med 1992; 327: 12721278.
  • 14
    Clifford GM, Smith JS, Plummer M, Munoz N, Franceschi S. Human papillomavirus types in invasive cervical cancer worldwide: A meta-analysis. Br J Cancer 2003; 88: 6373.
  • 15
    Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant 2007; 7: 941–948.
  • 16
    Birkeland SA, Lokkegaard H, Storm HH. Cancer risk in patients on dialysis and after renal transplantation. Lancet 2000; 355: 18861887.
  • 17
    Adami J, Gabel H, Lindelof B et al. Cancer risk following organ transplantation: A nationwide cohort study in Sweden. Br J Cancer 2003; 89: 12211227.
  • 18
    Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States [see comment]. Am J Transplant 2004; 4: 905913.
  • 19
    FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med 2007; 356: 19151927.
  • 20
    Garland SM, Hernandez-Avila M, Wheeler CM et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med 2007; 356: 19281943.
  • 21
    Newall AT, Beutels P, Wood JG, Edmunds WJ, MacIntyre CR. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007; 7: 289296.
  • 22
    Dyall-Smith D, Trowell H, Mark A, Dyall-Smith M. Cutaneous squamous cell carcinomas and papillomaviruses in renal transplant recipients: A clinical and molecular biological study. J Dermatol Sci 1991; 2: 139146.
  • 23
    Chen K, Craig JC, Shumack S. Oral retinoids for the prevention of skin cancers in solid organ transplant recipients: A systematic review of randomized controlled trials. Br J Dermatol 2005; 152: 518523.
  • 24
    Han PKJ. Historical changes in the objectives of the periodic health examination. Ann Intern Med 1997; 127: 910917.
  • 25
    Wilson JMG, Jungner G. Principles and Practice of Screening for Disease. 22[11], 473. Geneva : Public Health Papers, World Health Organisation, 1968.
  • 26
    Biesheuvel C, Barratt A, Howard K, Houssami N, Irwig L. Effects of study methods and biases on estimates of invasive breast cancer overdetection with mammography screening: A systematic review. Lancet Oncol 2007; 8: 11291138.
  • 27
    Lerman C, Trock B, Rimer BK, Boyce A, Jepson C, Engstrom PF. Psychological and behavioral implications of abnormal mammograms. Ann Intern Med 1991; 114: 657661.
  • 28
    Castellanos MR, Paramanathan K, El-Sayegh S, Forte F, Buchbinder S, Kleiner M. Breast cancer screening in women with chronic kidney disease: The unrecognized effects of metastatic soft-tissue calcification. Nature Clin Prac Nephrol 2008; 4: 337341.
  • 29
    Baildam AD, Higgins RM, Hurley E et al. Cyclosporin A and multiple fibroadenomas of the breast. Br J Surg 1996; 83: 17551757.
  • 30
    Catalona WJ, Loeb S, Han M. Viewpoint: Expanding prostate cancer screening. Ann Intern Med 2006; 144: 441443.
  • 31
    Hoffman RM. Viewpoint: Limiting prostate cancer screening. Ann Intern Med 2006; 144: 438440.
  • 32
    American College of Obstetricians and Gynecologists. ACOG practice bulletin. No. 42 breast cancer screening. Int J Gynaecol Obstet 2003; 81: 313323.
  • 33
    Tabar L, Gad A, Holmberg L, Ljungquist U. Significant reduction in advanced breast cancer. Results of the first seven years of mammography screening in Kopparberg, Sweden. Diagnos Imag Clin Med 1985; 54: 158164.
  • 34
    Rex DK. Colorectal cancer screening: A guide to the guidelines. Can J Gastroenterol 1999; 13: 397402.
  • 35
    Towler B, Irwig L, Glasziou P, Kewenter J, Weller D, Silagy C. A systematic review of the effects of screening for colorectal cancer using the faecal occult blood test, hemoccult. BMJ 1998; 317: 559565.
  • 36
    American College of Obstetricians and Gynecologists. ACOG practice bulletin no. 45. Cervical cytology screening. Int J Gynecol Obstet 2003; 83: 237247.
  • 37
    U.S Preventive Services. Screening for prostate cancer: Recommendation and rationale. Ann Intern Med 2002; 137: 915916.
  • 38
    McMahon BJ, London T. Workshop on screening for hepatocellular carcinoma. J Natl Cancer Inst 1991; 83: 916919.
  • 39
    Bruun L, Ekberg H, Bjork T, Lilja H, Hoglund P, Christensson A. Rapid elimination by glomerular filtration of free prostate specific antigen and human kallikrein 2 after renal transplantation. J Urol 2004; 171: 14321435.
  • 40
    Wong G, Howard K, Craig JC, Chapman JR. Cost-effectiveness of colorectal cancer screening in renal transplant recipients. Transplantation 2008; 85: 532541.
  • 41
    Kiberd BA, Keough-Ryan T, Clase CM. Screening for prostate, breast and colorectal cancer in renal transplant recipients. Am J Transplant 2003; 3: 619625.